touchPODCAST

touchMDT for touchRESPIRATORY

What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.

The multidisciplinary team

Radiation oncologist – Prof. Suresh Senan

Pulmonologist – Dr Lizza Hendriks, 

Medical oncologist – Dr Jacob Sands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchMDT for touchRESPIRATORY

What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.

The multidisciplinary team

Medical oncologist – Dr Jacob Sands

Radiation oncologist – Prof. Suresh Senan

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchMDT for touchRESPIRATORY

What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.

The multidisciplinary team:

Pulmonologist – Dr Lizza Hendriks, 

Radiation oncologist – Prof. Suresh Senan

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchMDT for touchONCOLOGY

What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects.

The multidisciplinary team

Radiation oncologist – Prof. Suresh Senan

Pulmonologist – Dr Lizza Hendriks, 

Medical oncologist – Dr Jacob Sands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchMDT for touchONCOLOGY

What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.

The multidisciplinary team

Medical oncologist – Dr Jacob Sands

Radiation oncologist – Prof. Suresh Senan

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchMDT for touchONCOLOGY

What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.

The multidisciplinary team:

Pulmonologist – Dr Lizza Hendriks, 

Radiation oncologist – Prof. Suresh Senan

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES

• Prof. Antoni Torres, University of Barcelona, Spain

This touchPODCAST is for HCPs outside of the UK.

www.touchINFECTIOUS DISEASES.com 

touchCONGRESS for touchONCOLOGY

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

• Data reviews with Prof. Rosti

Clinical themes

1. Approved and emerging TKIs for CML in the first-line setting

The internationally renowned multiple myeloma expert faculty

• Prof. Gianantonio Rosti: Meldola, Italy

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. 

For further information visit our website: TBC

touchCONGRESS for touchHAEMATOLOGY

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

• Data reviews with Prof. Rosti

Clinical themes

1. Approved and emerging TKIs for CML in the first-line setting

The internationally renowned multiple myeloma expert faculty

• Prof. Gianantonio Rosti: Meldola, Italy

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. 

For further information visit our website: TBC

touchPANEL DISCUSSION for touchNEUROLOGY

Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology. 

The experts

• Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA 

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Lundbeck. This activity is jointly provided by USF Health and touchIME in collaboration with the Gerontological Society of America (GSA).

For further information visit:

https://touchneurologyime.org/cme/curriculums/agitation-in-alzheimers-dementia/